Skip to main content
SAREUM HOLDINGS PLC logo

SAREUM HOLDINGS PLC — Investor Relations & Filings

Ticker · SAR ISIN · GB00BMC3RJ87 LEI · 213800PKERN2DY8FFM72 IL Manufacturing
Open in API
Filings indexed 348 across all filing types
Latest filing 2026-05-01 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL SAR

About SAREUM HOLDINGS PLC

https://www.sareum.com/

Sareum Holdings PLC is a clinical-stage small molecule company that discovers and develops next-generation kinase inhibitors for the treatment of autoimmune diseases and cancer. The company's research is primarily focused on the TYK/JAK kinase cell signalling family, with a specific emphasis on developing dual inhibitors of TYK2 and JAK1. This approach is pursued for its potential to offer superior efficacy compared to agents that target only one of these kinases. Its development pipeline includes SDC-1801, a potential oral therapy for autoimmune diseases, as well as other programs targeting cancer and viral infections.

Recent filings

Filing Released Lang Actions
Exercise of Warrants
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Sareum Holdings plc regarding the exercise of warrants and the subsequent issuance and admission of new ordinary shares to trading on AIM. It includes details about the number of shares issued, the price, and the total voting rights after the issuance. There is no financial statement, detailed financial analysis, or management discussion present. The document is relatively short (4208 characters) and serves as a regulatory announcement about a capital change event. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2026-05-01 English
Half-Year Report for Six Months Ended 31 Dec 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Report for the Six Months Ended 31 December 2025' and contains detailed financial highlights, operational updates, and an Executive Chairman's statement. It provides substantive financial data (cash position, administrative expenses, loss before tax) for an interim period. It is not a mere announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2026
2026-03-12 English
Notice of Results and Investor Presentation
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Sareum Holdings PLC regarding the upcoming release of their interim financial results and an associated investor presentation. It does not contain the actual financial report or the presentation slides themselves, but rather serves as a notification of when these will be published and how to attend the event. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-03-03 English
Restart of Phase 2-enabling toxicology programme
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces the restart of a specific clinical development program (Phase 2-enabling toxicology for SDC-1801) by Sareum Holdings PLC. It does not constitute a full financial report, an earnings release, or a governance document, but rather a corporate update on operational/clinical progress. As it is a general regulatory announcement regarding company operations that does not fit into more specific categories like M&A or share issues, it is classified as a Regulatory Filing (RNS).
2026-02-17 English
Form 8.3 - Oxford Biomedica plc
Major Shareholding Notification Classification · 100% confidence The document is a 'Form 8.3' disclosure, which is a standard regulatory filing required under the UK Takeover Code for persons with interests in relevant securities representing 1% or more of an offeror or offeree. This document specifically details shareholdings and positions in Oxford Biomedica plc. Since it is a regulatory disclosure regarding share ownership thresholds and takeover-related activity, it falls under the 'Major Shareholding Notification' category.
2026-01-23 English
Group of companies' accounts made up to 2025-06-30
Regulatory Filings
2025-12-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.